These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Case of Intestinal GIST with Long-Term Survival after Multidisciplinary Treatment, Including Surgical Resection for Liver Metastasis].
    Author: Uraoka M, Okada T, Fujimoto Y, Yamamura M, Ueno T.
    Journal: Gan To Kagaku Ryoho; 2020 Jan; 47(1):147-149. PubMed ID: 32381887.
    Abstract:
    A 54-year-old male underwent partial resection of the ileum for gastrointestinal stromal tumor(GIST). Although it was a high-risk GIST, he was followed-up without chemotherapy. Nineteen months after the initial operation, an EOB-MRI showed a mass in the liver(S8). As it had increased in size in 4 months of follow-up, 400mg/day of imatinib was started for the diagnosis of liver metastasis. The patient experienced PR 6 months after the initiation of chemotherapy and underwent partial hepatectomy. Imatinib 400mg/day was re-administered after hepatectomy, and the disease was well controlled for 16 months. Imatinib is acceptable as the first-line therapy for unresectable and metastatic GIST. The significance of surgical intervention remains unclear for liver metastasis in GIST; however, it could remain uncontrolled with surgery alone and requires concomitant imatinib therapy. On the other hand, imatinib could be beneficial and its life-long continuation is critical, but most patients eventually develop drug resistance. Complete resection of the metastatic site along with chemotherapy could lead to reduction of secondary resistance to imatinib and prolong the survival rate.
    [Abstract] [Full Text] [Related] [New Search]